European Medicines Agency recommends approval of Gazyvaro for chronic lymphocytic leukaemia

View source ↗

Summary

The European Medicines Agency recommends approval of Gazyvaro for chronic lymphocytic leukemia, supporting its use for this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Gazyvaro (obinutuzumab)